688105 · Nanjing Vazyme Biotech Co., Ltd. Class A

24.24

CNY

-1.28 (-5.016%)

21/08/2026 12:00:00 AM

Price change (7D)

Unlock stock Insights

Create a free account to unlock price targets, recommendations, and commentary.

Overview

Market Cap

Yuan13.19B

498.50

EV/EBITDA

62

DIV Yield

1.9%

Payout Ratio

0%

MQV Rating

5Very Weak

As at 21/08/2026 12:00:00 AM

Price Chart

Description

Nanjing Vazyme Biotech Co., Ltd. engages in the research and development, and production of antibody drugs. Its products include Biological reagents and In vitro diagnostic products. The biological reagents products consist of polymerase chain reaction series, molecular cloning series, reverse record series, gene sequencing series, bio-assay series, and cell and protein series. The In vitro diagnostic products encompass point-of-care testing diagnostic reagents and instrument. The company was founded on March 16, 2012 and is headquartered in Nanjing, China.

All-Companies
All-Consensus
Consensus Expensive
HALO All
Volume Spike

Key Fundamentals

EPS 3 yr Growth

-102.80%

EBITDA Margin

7.00%

Operating Cashflow

¥297m

Free Cash Flow Return

7.40%

ROIC

-0.40%

Interest Coverage

3.60

Quick Ratio

3.20

Performance

52 weeks range

Low 12.89 - 26.1

Trade Value (12mth)

US$3,071,453.00

1 week

4.5%

1 month

50.65%

YTD

61.91%

1 year

34.26%

All time high

100.39

Additional Data

Shares Outstanding (Fully Diluted)

517m

HALO Sector

Healthcare

Next Company Report Date

23-Apr-27

Next Ex Dividend Date

03-Jun-26

Next Dividend Pay Date

03-Jun-26

Reporting Currency

CNY

Short Sell (% of issue)

0.00

Consensus

Unlock full consensus

Consensus score

/10

Recommendation

Buy

Target price

Deviation

Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Very Strong

Halo Model

Mqv

Very Weak

Garp

Very Weak

Mqv Small

Neutral

Momentum

Price

Strong

Earnings

Very Weak

Growth

Earnings

Strong

Dividends

Neutral

Quality

Capital Efficiency

Very Weak

Balance Sheet

Very Weak

Valuation

Unlock full dataset

Value

Consensus

Yield

News & Announcements

No announcements available.

Key Stakeholders

Name	Title
Lin Cao	Individual
China Life Private Equity Investment Co. Ltd.	Subsidiary
Qi Yang	Individual
Nanjing Nuotai Venture Capital Partnership LP	Private Company
Danen Capital Co. Ltd.	Private Company